Following the Brussels conference, VISION EUROPE 2030 continued its discourse globally, extending the conversations and collaborations initiated during the two-day event. Between September and November 2025, high-level meetings were held in New York, Japan, Oman and China, highlighting how Europe’s policy, innovation, and health systems intersect with global efforts in precision oncology and non-communicable disease prevention.
These follow-up activities focused on translating pilot projects into system-level change, fostering international collaboration, and ensuring that innovations reach patients worldwide. Key objectives included:
These follow-up activities underline VISION EUROPE 2030’s mission: closing the “last mile” between scientific potential and real-world impact, ensuring that precision medicine, advanced diagnostics, and patient-centred care are implemented efficiently, consistently, and equitably across Europe and beyond.
At the end of September, VISION EUROPE 2030 started extending its discussions beyond Europe to explore how innovations in cancer and non-communicable diseases (NCDs) can be translated into tangible global impact. The “Last Mile Series”, held in New York in September 2025, consisted of three high-level events, each building on the insights from Brussels and forming a unified call to close the gap between scientific potential and real-world access.
The series opened at the Italian Cultural Institute, with the event titled “The Last Mile – Screening, Early Detection and Treatment: Driving Investment, Innovation, and Alignment.” Leading speakers and delegates, including Phil Hogan, Roberto Grasso, Adda Bounedjar, Josep Figueras, Hesham Elghazaly and Zisis Kozlakidis, all key speakers at Vision Europe 2030 in Brussels, examined how strategic investment, coordinated implementation, and cross-sector cooperation can accelerate access to prevention, early detection, and treatment. This event set the stage for a global campaign aimed at translating evidence-based policy into practical action, reinforcing Vision Europe’s commitment to equitable and timely innovation. The second event, titled “The Last Mile: Bridging the Cancer & NCD Innovation Gap with AI, Early Detection and Equitable Access”, took place at the United Nations Headquarters and was co-hosted by the Permanent Mission of the Philippines. This session brought Vision Europe’s priorities into the heart of multilateral diplomacy, emphasizing the urgency of equitable access to innovation across regions. Participants highlighted the value of aligned governance, collaborative financing models, and data-driven strategies to ensure that breakthroughs in cancer and NCD care reach all populations. Kara Alikpala, who served as moderator for the session, helped guide discussions and facilitate dialogue among international delegates. Strong engagement from international delegates validated the global relevance of Vision Europe’s agenda.
The series concluded with a high-level luncheon at the Permanent Mission of Switzerland to the United Nations, bringing together distinguished leaders such as Ruggero De Maria and Josep Figueras, who both were present in Brussels and played a central role in the New York discussions, but also new speakers who added to the conversation: among them Harold Varmus, who received the Nobel Prize for Medicine in 1989, and Jonathan A. Lal, from SHUATS University, India. The conversation focused on the central challenge of implementing innovation across cancer, NCDs, and rare diseases, highlighting the importance of sustainable financing, equitable access, and coordinated international efforts.
Held in Yokohama, this follow-up event focused on translating world-class scientific capability into everyday clinical benefit. Titled “From Pipeline to Patient: Delivering on the Promise of Precision Oncology and Beyond”, the meeting explored how Japan can convert consensus into near-term action across early detection, stratified screening, real-world evidence, clinical trials, and sustainable financing.
Building on the VISION EUROPE 2030 agenda, discussions emphasized the need for robust governance frameworks, interoperable data systems, value-based reimbursement, workforce capacity, patient literacy, and responsible use of AI. Japan’s experience demonstrated feasible pathways for standardized testing, minimal residual disease (MRD) deployment, and data-driven oncology, showing how scientific breakthroughs can be translated into practical, equitable care.
The Yokohama Forum also served as the next step following the New York sessions, where a broad coalition of governments, UN agencies, development banks, industry, academia, and patient organizations endorsed the “Consensus Framework: The Last Mile Action Agenda”. This framework outlined three shared priorities:
Political and technical discussions underscored that innovation without delivery risks deepening inequities. Speakers like Denis Horgan highlighted practical models that can shorten the distance between evidence and patient benefit. By convening leading clinicians, scientists and policymakers, this follow-up event aligned with the broader goals of VISION EUROPE 2030, reinforcing the commitment to equitable access to innovation, stronger cancer systems, and meaningful improvements for patients, not only in Europe but worldwide.
The VISION EUROPE 2030 follow-up event in Muscat, Oman, titled “Advancing Translational Education: Regional Strategies for Precision Medicine in the MENA Region”, brought together regional partners to discuss tailored implementation strategies for the Gulf and neighbouring regions. Held under the theme “Global Unity for Cancer Prevention: Empowering Communities” during the World Cancer Congress 2025, the forum provided a major platform to advance the VISION EUROPE agenda, strengthen global partnerships, and reduce disparities in cancer care.
Discussions focused on building sustainable screening and vaccination programs adapted to local epidemiology and healthcare infrastructures, strengthening workforce capacity, and designing regulatory and financing frameworks that reflect regional realities. Participants explored how training, communication, and regional cooperation can prepare health systems for precision medicine, translating global best practices into actionable local strategies. Speakers addressed key areas such as workforce development, patient navigation, and operational readiness for advanced diagnostics and therapies. The event emphasized that equitable access to innovation requires not only technology but also education, capacity building, and sustained collaboration between regional and global stakeholders.
The Oman meeting reinforced the overarching VISION EUROPE 2030 message: global strategies succeed only when they are carefully adapted to regional contexts, ensuring tangible impact and practical implementation in diverse health systems.
At the CACA–ICPC Summit in Kunming, global leaders convened to explore how artificial intelligence and digital tools can enhance, rather than replace, person-centred cancer care. The summit built on the foundations of VISION EUROPE 2030, reinforcing the principle that technology must serve patients and professionals, supporting care without compromising human connection.
Speakers including Daniela Chieffo, who also played a key role at VISION EUROPE 2030 in Brussels, where she set the scene for the session “Precision Frontiers in Chronic Disease – A Global Strategy for Cancer Risk, Trials and Treatment, stressed that technological innovation must remain anchored in compassion, ethics, and patient partnership. Discussions focused on integrating psycho-oncological support into high-tech care pathways, deploying AI responsibly with fairness, explainability, and transparency, and establishing governance, reimbursement, privacy, and infrastructure frameworks that enable equitable access.
A second session connected European and global policy efforts, highlighting cross-border collaboration, education, and infrastructure development as critical enablers for delivering human-centred, ethically sound care. The Kunming summit showcased the global resonance of Vision Europe’s core principles: ethical innovation, equity in access, and putting patients at the centre of every decision, demonstrating that technological advances must be matched by thoughtful implementation and societal readiness.
From Brussels to New York, Yokohama, Muscat and Kunming, the 2025 meetings have converged on the same conclusion: the decisive challenge for this decade is not discovering more technologies, but delivering what we already have – fairly, consistently and at scale.
